nach oben

Erschienen in:

12.04.2019 | leitlinien für die praxis

Insulinpumpentherapie bei Kindern, Jugendlichen und Erwachsenen (Update 2019)

verfasst von: Ingrid Schütz-Fuhrmann, Marietta Stadler, Sandra Zlamal-Fortunat, Birgit Rami-Merhar, Elke Fröhlich-Reiterer, Sabine E. Hofer, Julia Mader, Michael Resl, Martin Bischof, Alexandra Kautzky-Willer, Raimund Weitgasser

Erschienen in: Wiener klinische Wochenschrift | Sonderheft 1/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Dieses Positionspapier zur Anwendung der subkutanen Insulinpumpentherapie (CSII) bei Diabetes mellitus basiert auf aktueller Evidenz zu Sicherheit und Vor-und Nachteile der CSII, insbesondere im Hinblick auf glykämische Kontrolle, Hypoglykämie, ketoazidotische Entgleisung, Lebensqualität und Anwendung in der Schwangerschaft. Dieser Artikel beinhaltet die Empfehlungen der Österreichischen Diabetes Gesellschaft für die klinische Anwendung der Insulinpumpentherapie bei Kindern, Jugendlichen und Erwachsenen.

Vorheriger Artikel Insulintherapie bei Typ 2 Diabetes mellitus (Update 2019)

Nächster Artikel Ernährungsempfehlungen bei Diabetes mellitus (Update 2019)

Diabetes Epidemiology Research International Mortality Study Group.. International evaluation of cause-specific mortality and IDDM. Diabetes Care. 1991;14(1):55–60.CrossRef

Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. 2002;324(7339):70.CrossRef

Jeitler K, Horvath K, Berghold A, Gratzer TW, Neeser K, Pieber TR, et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia. 2008;51(6):941–51.CrossRef

Misso ML, Egberts KJ, Page M, O’Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2010; https://doi.org/10.1002/14651858.CD005103.pub2.CrossRefPubMed

Retnakaran R, Hochman J, Devries JH, Hanaire-Broutin H, Heine RJ, Melki V, et al. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care. 2004;27(11):2590–6.CrossRef

Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, et al. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care. 2005;28(3):533.CrossRef

Sherr J, Tamborlane WV. Past, present, and future of insulin pump therapy: better shot at diabetes control. Mt Sinai J Med. 2008;75(4):352–61.CrossRef

Pankowska E, Blazik M, Dziechciarz P, Szypowska A, Szajewska H. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatr Diabetes. 2009;10(1):52–8.CrossRef

Bohn B, Karges B, Vogel C, Otto KP, Marg W, Hofer SE, Fröhlich-Reiterer E, Holder M, Plamper M, Wabitsch M, Kerner W, Holl RW, DPV Initiative. 20 years of pediatric benchmarking in Germany and Austria: age-dependent analysis of longitudinal follow-up in 63,967 children and adolescents with type 1 diabetes. 1. PLoS ONE. 2016;11(8):e160971–2016. https://doi.org/10.1371/journal.pone.0160971.CrossRefPubMedPubMedCentral

10.

Sherr JL, Hermann JM, Campbell F, Foster NC, Hofer SE, Allgrove J, Maahs DM, Kapellen TM, Holman N, Tamborlane WV, Holl RW, Beck RW, Warner JT, T1D Exchange Clinic Network, DPV Initiative, National Paediatric Diabetes Audit and the Royal College of Paediatrics and Child Health registries. Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries. Diabetologia. 2016;59(1):87–91. https://doi.org/10.1007/s00125-015-3790-6.CrossRefPubMed

11.

Maahs DM, Hermann JM, DuBose SN, Miller KM, Heidtmann B, DiMeglio LA, Rami-Merhar B, Beck RW, Schober E, Tamborlane WV, Kapellen TM, Holl RW, T1D Exchange Clinic Network. Contrasting the clinical care and outcomes of 2,622 children with type 1 diabetes less than 6 years of age in the United States T1D Exchange and German/Austrian DPV registries. Diabetologia. 2014;57(8):1578–85. https://doi.org/10.1007/s00125-014-3272-2.CrossRefPubMed

12.

Karges B, Schwandt A, Heidtmann B, Kordonouri O, Binder E, Schierloh U, Boettcher C, Kapellen TH, Holl RW. Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes. JAMA. 2017;318(14):1358–66.CrossRef

13.

Zabeen B, Craig ME, Virk SA, Pryke A, Chan AK, Cho YH, Benitez-Aguirre PZ, Hing S, Donaghue KC. Insulin pump therapy is associated with lower rates of retinopathy and peripheral nerve abnormality. PLoS ONE. 2016;11(4):e153033. https://doi.org/10.1371/journal.pone.0153033.CrossRefPubMedPubMedCentral

14.

Bachran R, Beyer P, Klinkert C, Heidtmann B, Rosenbauer J, Holl RW. Basal rates and circadian profiles in continuous subcutaneous insulin infusion (CSII) differ for preschool children, prepubertal children, adolescents and young adults. Pediatr Diabetes. 2012;13(1):1–5.CrossRef

15.

Adolfsson P, Ziegler R, Hanas R. Continuous subcutaneous insulin infusion: special needs for children. Pediatr Diabetes. 2017;18(4):255–61. https://doi.org/10.1111/pedi.12491.CrossRefPubMed

16.

Reznik Y, Cohen O, Aronson R, Conget I, Runzis S, Castaneda J, et al. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. Lancet. 2014;384(9950):1265–72.CrossRef

17.

Pickup JC, Reznik Y, Sutton AJ. Glycemic control during continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: individual patient data Meta-analysis and Meta-regression of randomized controlled trials. Diabetes Care. 2017;40(5):715–22. https://doi.org/10.2337/dc16-2201.CrossRefPubMed

18.

Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008;25(7):765–74.CrossRef

19.

Berghaeuser MA, Kapellen T, Heidtmann B, Haberland H, Klinkert C, Holl RW. Continuous subcutaneous insulin infusion in toddlers starting at diagnosis of type 1 diabetes mellitus. A multicenter analysis of 104 patients from 63 centres in Germany and Austria. Pediatr Diabetes. 2008;9(6):590–5.CrossRef

20.

Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363(4):311–20.CrossRef

21.

Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, et al. Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6‑month continuation phase. Diabetes Care. 2011;34(11):2403–5.CrossRef

22.

Slover RH, Welsh JB, Criego A, Weinzimer SA, Willi SM, Wood MA, et al. Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Pediatr Diabetes. 2012;13(1):6–1120.CrossRef

23.

Hermanides J, Norgaard K, Bruttomesso D, Mathieu C, Frid A, Dayan CM, et al. Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled trial. Diabet Med. 2011;28(10):1158–67.CrossRef

24.

Battelino T, Nimri R, Dovc K, Phillip M, Bratina N. Prevention of hypoglycemia with predictive low glucose insulin suspension in children with type 1 diabetes: a randomized controlled trial. Diabetes Care. 2017;40(6):764–70. https://doi.org/10.2337/dc16-2584.CrossRefPubMed

25.

Kordonouri O, Pankowska E, Rami B, Kapellen T, Coutant R, Hartmann R, et al. Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of treatment. Diabetologia. 2010;53(12):2487–95.CrossRef

26.

Danne T, Battelino T, Jarosz-Chobot P, Kordonouri O, Pankowska E, Ludvigsson J, et al. Establishing glycaemic control with continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes: experience of the PedPump Study in 17 countries. Diabetologia. 2008;51(9):1594–601.CrossRef

27.

Bergenstal RM, Welsh JB, Shin JJ. Threshold insulin-pump interruption to reduce hypoglycemia. N Engl J Med. 2013;369(15):1474.CrossRef

28.

Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA. 2013;310(12):1240–7.CrossRef

29.

Choudhary P, Ramasamy S, Green L, Gallen G, Pender S, Brackenridge A, et al. Real-time continuous glucose monitoring significantly reduces severe hypoglycemia in hypoglycemia-unaware patients with type 1 diabetes. Diabetes Care. 2013;36(12):4160–2.CrossRef

30.

Danne T, Tsioli C, Kordonouri O, Blaesig S, Remus K, Roy A, et al. The PILGRIM study: in silico modeling of a predictive low glucose management system and feasibility in youth with type 1 diabetes during exercise. Diabetes Technol Ther. 2014;16(6):338–47.CrossRef

31.

Biester T, Kordonouri O, Holder M, Remus K, Kieninger-Baum D, Wadien T, Danne T. Let the algorithm do the work: reduction of hypoglycemia using sensor-augmented pump therapy with predictive insulin suspension (smartguard) in pediatric type 1 diabetes patients. Diabetes Technol Ther. 2017;19(3):173–82. https://doi.org/10.1089/dia.2016.0349.CrossRefPubMedPubMedCentral

32.

Sherr JL, Tauschmann M, Battelino T, de Bock M, Forlenza G, Roman R, Hood KK, Maahs DM. ISPAD clinical practice consensus guidelines 2018 diabetes technologies. Pediatr Diabetes. 2018; https://doi.org/10.1111/pedi.12731.CrossRefPubMedPubMedCentral

33.

Attia N, Jones TW, Holcombe J, Tamborlane WV. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM. Diabetes Care. 1998;21(5):817–21.CrossRef

34.

Knight G, Jennings AM, Boulton AJ, Tomlinson S, Ward JD. Severe hyperkalaemia and ketoacidosis during routine treatment with an insulin pump. Br Med J. 1985;291(6492):371–2.CrossRef

35.

Mecklenburg RS, Guinn TS. Complications of insulin pump therapy: the effect of insulin preparation. Diabetes Care. 1985;8(4):367–70.CrossRef

36.

Realsen J, Goettle H, Chase HP. Morbidity and mortality of diabetic ketoacidosis with and without insulin pump care. Diabetes Technol Ther. 2012;14(12):1149–54.CrossRef

37.

Farrar D, Tuffnell DJ, West J. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev. 2007; https://doi.org/10.1002/14651858.CD005542.pub3.CrossRefPubMed

38.

Mukhopadhyay A, Farrell T, Fraser RB, Ola B. Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women: a systematic review and metaanalysis of randomized, controlled trials. Am J Obstet Gynecol. 2007;197(5):447–56.CrossRef

39.

Kernaghan D, Farrell T, Hammond P, Owen P. Fetal growth in women managed with insulin pump therapy compared to conventional insulin. Eur J Obstet Gynecol Reprod Biol. 2008;137(1):47–9.CrossRef

40.

Kallas-Koeman MM, Kong JM, Klinke JA, Butalia S, Lodha AK, Lim KI, et al. Insulin pump use in pregnancy is associated with lower HbA1c without increasing the rate of severe hypoglycaemia or diabetic ketoacidosis in women with type 1 diabetes. Diabetologia. 2014;57(4):681–9.CrossRef

41.

Gabbe SG, Holing E, Temple P, Brown ZA. Benefits, risks, costs, and patient satisfaction associated with insulin pump therapy for the pregnancy complicated by type 1 diabetes mellitus. Am J Obstet Gynecol. 2000;182(6):1283–91.CrossRef

42.

Steineck I, Cederholm J, Eliasson B, Rawshani A, Eeg-Olofsson K, Svensson AM, Zethelius B, Avdic T, Landin-Olsson M, Jendle J, Gudbjörnsdóttir S, Swedish National Diabetes Register. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18,168 people with type 1 diabetes: observational study. BMJ. 2015;350:h3234. https://doi.org/10.1136/bmj.h3234.CrossRefPubMedPubMedCentral

43.

Klupa T, Benbenek-Klupa T, Malecki M, Szalecki M, Sieradzki J. Clinical usefulness of a bolus calculator in maintaining normoglycaemia in active professional patients with type 1 diabetes treated with continuous subcutaneous insulin infusion. J Int Med Res. 2008;36(5):1112–6.CrossRef

44.

Jones SM, Quarry JL, Caldwell-McMillan M, Mauger DT, Gabbay RA. Optimal insulin pump dosing and postprandial glycemia following a pizza meal using the continuous glucose monitoring system. Diabetes Technol Ther. 2005;7(2):233–40.CrossRef

45.

O’Connell MA, Gilbertson HR, Donath SM, Cameron FJ. Optimizing postprandial glycemia in pediatric patients with type 1 diabetes using insulin pump therapy: impact of glycemic index and prandial bolus type. Diabetes Care. 2008;31(8):1491–5.CrossRef

46.

Pozzilli P, Battelino T, Danne T, Hovorka R, Jarosz-Chobot P, Renard E. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. Diabetes Metab Res Rev. 2016;32(1):21–39.CrossRef

47.

Cummins E, Royle P, Snaith A, Greene A, Robertson L, McIntyre L, et al. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. Health Technol Assess. 2010;14(11):iii–iv, xi–xvi, 1–181.CrossRef

48.

Golden SH, Brown T, Yeh HC, Maruthur N, Ranasinghe P, Berger Z, et al. Methods for insulin delivery and glucose monitoring: comparative effectiveness. Report No.: 12-EHC036-EF. Rockville: Agency for Healthcare Research and Quality; 2012.

49.

Cherubini V, Gesuita R, Bonfanti R, Franzese A, Frongia AP, Iafusco D, et al. Health-related quality of life and treatment preferences in adolescents with type 1 diabetes. The VIPKIDS study. Acta Diabetol. 2014;51(1):43–51.CrossRef

50.

Skogsberg L, Fors H, Hanas R, Chaplin JE, Lindman E, Skogsberg J. Improved treatment satisfaction but no difference in metabolic control when using continuous subcutaneous insulin infusion vs. multiple daily injections in children at onset of type 1 diabetes mellitus. Pediatr Diabetes. 2008;9(5):472–9.CrossRef

51.

Lukacs A, Kiss-Toth E, Varga B, Soos A, Takac P, Barkai L. Benefits of continuous subcutaneous insulin infusion on quality of life. Int J Technol Assess Health Care. 2013;29(1):48–52.CrossRef

Titel: Insulinpumpentherapie bei Kindern, Jugendlichen und Erwachsenen (Update 2019)
verfasst von: Ingrid Schütz-Fuhrmann
Marietta Stadler
Sandra Zlamal-Fortunat
Birgit Rami-Merhar
Elke Fröhlich-Reiterer
Sabine E. Hofer
Julia Mader
Michael Resl
Martin Bischof
Alexandra Kautzky-Willer
Raimund Weitgasser
Publikationsdatum: 12.04.2019
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe Sonderheft 1/2019
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-019-1485-6

Springer Medizin Österreich

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2019

Diabetesmanagement im Krankenhaus (Update 2019)

Diabetes mellitus im Kindes- und Jugendalter (Update 2019)

Gestationsdiabetes (GDM) (Update 2019)

Diabetesschulung und -beratung bei Erwachsenen mit Diabetes (Update 2019)

Lebensstil: körperliche Aktivität und Training in der Prävention und Therapie des Typ 2 Diabetes mellitus (Update 2019)

Ernährungsempfehlungen bei Diabetes mellitus (Update 2019)